Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NV1FGF in Intermittent Claudication
NCT01157871Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2004
- Primary completion
- Aug 2005
- Modality
- Gene Editing, Gene Silencing, Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 2 trial of Riferminogene pecaplasmid in peripheral arterial occlusive disease (PAOD), sponsored by Sanofi. Started Jun 2004; status: completed.
02
Drugs
Riferminogene pecaplasmid
03
Conditions
peripheral arterial occlusive disease (PAOD)
Beyond the preview
Go deeper on NCT01157871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01157871.